Combining Shockwave Therapy with Drug-Eluting Stents for Peripheral Artery Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical investigation aims to assess the safety and efficacy of using Shockwave Intravascular Lithotripsy in conjunction with a polymer-coated Drug Eluting Stent for patients with calcified femoropopliteal disease over a 12-month period. The study focuses on individuals diagnosed with symptomatic peripheral artery disease, specifically those with significant stenosis in the superficial femoral artery and/or proximal popliteal artery. Participants will undergo treatment and be monitored for outcomes related to their vascular health and symptom relief.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject must be between 21 and 85 years old
* Clinical diagnosis of symptomatic peripheral artery disease, defined by Rutherford Becker Classification score 3-5
* Willing to comply with the specified follow-up evaluation
* Written informed consent prior to any study procedures
* Stenotic, restenotic after PTA or occlusive lesion(s) located in the native Superficial Femoral Artery (SFA) and/or proximal Popliteal Artery (PPA):

  1. Degree of stenosis ≥ 70% by visual agiographic assessment
  2. Vessel diameter ≥ 4 and ≥ 6 mm
  3. Total lesion length (or series of lesions) ≥ 30 mm and 210 mm (Note: Lesion segment(s) must be filly covered with one or two overlapping DES stent (s) be fully covered with one or two overlapping DES stent(s)
  4. Target lesion located at least three centimeters above the inferior edge of the femur
* Severity of calcification PACSS 3-4
* Patent infrapopliteal and popliteal artery; i.e. single vessel runoff or better with at least one of three vessels patent (\>50% stenosis) to the ankle or foot with no planned intervention.
* Study entry after successful target lesion crossing of the guidewire (guidewire located intraluminally or subintimally); Both crossing devices as well as retrograde recanalization can be used.
* Non-target lesion interventions to restore adequate blood flow, in the same index procedure are allowed. This intervention must be prior to the treatment of the study lesion and should be completed successfully.

Exclusion Criteria:

* Not treated ipsilateral significant (\>50%) stenosis of the iliac arteries
* Non severely calcified disease (absence of calcification, PACSS 1, PACSS 2)
* Significant (\>50%) stenosis of all infrapopliteal arteries, no patent artery to the foot
* Angiographic evidence of thrombus within the target vessel
* Thrombolysis within 72 hours prior to the index procedure
* Previously stented target lesion / vessel
* Subjects who have undergone prior surgery of the target lesion SFA/PPA to treat atherosclerotic disease
* Bypass Anastomosis stenosis
* Concomitant hepatic insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder or receiving immunosuppressant therapy
* Recent MI or stroke \<30 days prior to the index procedure
* Life expectancy less than 24 months
* Known or suspected active infection at the time of the index procedure
* Known or suspected major allergies or contraindications to aspirin, clopidogrel bisulfate (Plavix) and ticlopidine (Ticlid), heparin, or contrast agent
* Any significant medical condition which, in the investigator's opinion, may interfere with the subject's optimalparticipation in the study
* The subject is currently participating in another drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
* Female subjects pregnant, breastfeeding, of childbearing potential who are planning to become pregnant in the next 5 years.
* End-stage-renal disease
* Presence of Severe Ischemic Ulcers or frank gangrene (Rutherford class 6).

Where it's running

• Klinikum Hochsauerland
  Arnsberg, Germany Recruiting
• University Hospital Essen
  Essen, Germany Recruiting
• University Hospital Eppendorf
  Hamburg, Germany Recruiting
• SRH Klinikum Karlsbad-Langensteinbach
  Karlsbad, Germany Recruiting
• University Hospital LMU Munich
  Munich, Germany Recruiting
• St. Marien Hospital
  Lünen, Germany Not yet recruiting

Study contacts

• Principal investigator: Konstantinos Stavroulakis, MD — Vascular Department, LMU Munich
• Study coordinator: Annelena Held-Wehmöller, PhD
• Email: shockwave_des@fcre.eu
• Phone: +4915785128140

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing

  A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.

  Recruiting Second Affiliated Hospital of Nanchang University · Nanchang, Jang XI · NCT07881588

• Predictors of Major Adverse Limb Events After Iliac Artery Stenting

  This study tests what factors predict serious limb-related problems after iliac artery stenting in adults with peripheral artery disease.

  Recruiting I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · Milan, Mi · NCT07672249

• New prodrug CG-0255 Besylate vs Plavix in healthy adults

  This study tests whether CG-0255 Besylate works similarly to Plavix® in healthy adults to understand how the two drugs behave in the body.

  Recruiting Phase 1 Shanghai CureGene Pharmaceutical Co., Ltd. · Miami, Florida · NCT07619885

• Radial and Ulnar Access in Vascular Interventions Registry

  This registry tests how often radial or ulnar artery access is used and what happens afterward in routine vascular procedures.

  Recruiting Mersin Medicalpark Hastanesi · Mersin, Mezitli · NCT07614386

• Remote versus in-person 30-second sit-to-stand testing for people with peripheral artery disease

  This project will test whether doing the 30-second sit-to-stand test by video works as well as doing it in person for adults aged 18–65 with Fontaine stage I–II peripheral artery disease who have a smartphone.

  Recruiting Izmir Democracy University · Izmir, Balçova · NCT07497360

• Imaging plaque activity across the body in people with symptomatic peripheral arterial disease

  This project will use whole-body PET-CT and CT angiography with several tracers to see if imaging can detect inflammation, microcalcification, and clot activity in people with symptomatic peripheral arterial disease.

  Recruiting University of Edinburgh · Edinburgh, Midlothian · NCT07472049

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.